杭州安旭生物科技股份有限公司 投资者关系管理制度 杭州安旭生物科技股份有限公司 投资者关系管理制度 （2025 年 8 月修订） （一）透露或者发布尚未公开的重大事件信息，或者与依法披露的信息相冲 突的信息； 第一章 总 则 第一条 为了加强杭州安旭生物科技股份有限公司（以下简称"公司"）与投 资者之间的信息沟通，完善公司治理结构，切实保护投资者特别是社会公众投资 者的合法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司投资者关 系管理工作指引》、《上海证券交易所科创板股票上市规则》、《杭州安旭生物 科技股份有限公司章程》（以下简称"公司章程"）及其他有关法律、法规的规 定，结合公司实际情况，制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动 交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对 上市公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、 回报投资者、保护投资者目的的相关活动。 第三条 公司投资者关系管理工作应严格遵守《公司法》、《证券法》等有 关法律、法 ...

Group 1 - Jerry Holdings reported a net profit of 1.241 billion yuan for the first half of 2025, an increase of 14.04% year-on-year, with total revenue reaching 6.901 billion yuan, up 39.21% year-on-year [1] - Tian Tan Biological announced a net profit of 633 million yuan for the first half of 2025, a decrease of 12.88% year-on-year, with total revenue of 3.110 billion yuan, an increase of 9.47% year-on-year [2] - Shunbo Alloy achieved a net profit of 177 million yuan for the first half of 2025, a significant increase of 110.56% year-on-year, with total revenue of 7.126 billion yuan, up 11.75% year-on-year [7] Group 2 - Dashi Intelligent signed a contract for the Jingpai Building smart project with a total contract value of 34.06 million yuan, accounting for 1.07% of the company's audited revenue for 2024 [3] - Maglev Technology plans to invest 700 million yuan to establish a research and production base for maglev compressors, aiming to optimize product structure and enhance production capacity [4] - Koweil received government subsidies totaling 5.502 million yuan, which are expected to positively impact the company's profits for 2025 [5] Group 3 - Pengding Holdings reported a consolidated revenue of 3.002 billion yuan for July 2025, an increase of 12.28% compared to the same period last year [9] - Liuyou Group repurchased 544,500 shares at a price range of 18.29 to 18.36 yuan per share, totaling approximately 9.9828 million yuan [10] - Jin Xin Nong reported a sales revenue of 96.731 million yuan from pig sales in July 2025, with a total of 79,400 pigs sold [12] Group 4 - Jiangsu Huachen plans to use up to 70 million yuan of idle raised funds for cash management, investing in safe and liquid financial products [13] - Gongtong Pharmaceutical's subsidiary intends to purchase assets from an affiliate for 16.57 million yuan to build a wastewater treatment facility [15] - Tian Shi Li appointed Wang Yimin as the vice general manager, effective immediately [16] Group 5 - Zhejiang Yongqiang established a subsidiary in Indonesia with a registered capital of 230 billion Indonesian rupiah, focusing on overseas capacity investment and international trade [18] - Wangli Security received three invention patents, enhancing its product portfolio in security locks [20] - Shennong Group reported a sales revenue of 327 million yuan from pig sales in July 2025, with an average selling price of 14.73 yuan per kilogram [21] Group 6 - Dize Pharmaceutical's product DZD8586 received fast track designation from the FDA for treating relapsed refractory chronic lymphocytic leukemia [23] - Daqin Railway reported a cargo transportation volume of 31.79 million tons in July 2025, a year-on-year increase of 5.40% [24] - Xin Hongye's subsidiary won a bid for a nuclear-grade cable procurement project worth 81.58 million yuan [26] Group 7 - Hainan Hengbo established a wholly-owned subsidiary with a registered capital of 50 million yuan, focusing on technology services and new material technology research [26] - Changhong Huayi reported a net profit of 257 million yuan for the first half of 2025, an increase of 13.42% year-on-year, with total revenue of 6.628 billion yuan [27] - Haiguang Information achieved a net profit of 1.201 billion yuan for the first half of 2025, an increase of 40.78% year-on-year, with total revenue of 5.464 billion yuan [28] Group 8 - Dongmu Co. reported a net profit of 261 million yuan for the first half of 2025, an increase of 37.61% year-on-year, with total revenue of 2.930 billion yuan [29] - Hanma Technology announced the resignation of its executive vice president due to personal reasons [30] - Guangge Technology's shareholders plan to reduce their holdings by up to 4.04% of the company's shares [31] Group 9 - *ST Energy's subsidiary won a bid for an independent energy storage project with a total bid price of 320 million yuan for design and 301 million yuan for construction [32] - Chipeng Micro plans to reduce its holdings by up to 2% of the company's shares due to personal financial needs [33] - Ancar Detection announced a change in its controlling shareholder to Silicon Technology, with stock resuming trading [35] Group 10 - Dahao Technology's vice president is temporarily unable to perform duties due to health reasons [36] - Sanjiang Shopping's cooperation agreement with Hema will not be renewed after its expiration in March 2026 [37] - Huisheng Biological reported a net profit of 117 million yuan for the first half of 2025, a year-on-year increase of 325.88% [38] Group 11 - Dongshan Precision plans to increase capital in its subsidiary by 3.5 billion USD to support high-end PCB projects [39] - Yunnan Copper's subsidiary's bankruptcy liquidation application has been accepted by the court due to resource depletion [40] - Shanghai Bank's board member and chairman's qualifications have been approved by regulatory authorities [41] Group 12 - Junwei Electronics plans to acquire 100% of Flat Electronics Co., Ltd. for 2.6 billion yen to enter the film resistor market [42] - Daodaoquan's controlling shareholder plans to increase its stake in the company by 50 million to 100 million yuan [43] - Yinglian Co.'s subsidiary signed a strategic cooperation agreement with a well-known cylindrical battery company [45] Group 13 - Debang Technology's state integrated circuit fund plans to reduce its holdings by up to 3% of the company's shares [47] - Tianyi New Materials plans to sell part of its subsidiary's assets for 51.4 million yuan to improve cash flow [49] - Rongtai Co. intends to acquire 51% of Zhongshan Aoduo for 288 million yuan [51]

Core Viewpoint - Anxu Bio (688075.SH) plans to utilize up to RMB 4 billion of its temporarily idle self-owned funds to purchase low-risk, high-liquidity investment products through qualified financial institutions, with a usage period effective from September 18, 2025, for 12 months [1] Group 1 - The company intends to invest in safe and liquid financial products, including but not limited to principal-protected investment products, structured deposits, large-denomination certificates of deposit, and time deposits [1] - The investment will be executed through banks and securities companies that have legal operating qualifications [1] - The funds can be rolled over within the specified limit and duration [1]

Core Viewpoint - Tian Tan Biological Products (600161.SH) reported a total operating revenue of 3,110.39 million yuan for the first half of 2025, reflecting a year-on-year growth of 9.47%, while the net profit attributable to shareholders decreased by 12.88% [1] Group 1 - The increase in operating revenue is attributed to a growth in sales volume [1] - The decline in net profit is influenced by a decrease in product sales prices and changes in credit policies leading to reduced interest income [1] - The company operated 85 plasma collection companies, achieving a plasma collection of 1,361 tons, which represents a year-on-year increase of 0.7% [1]

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 当视角进一步聚焦至中国经济中心上海时，该地区的医药生物行业CFO薪酬溢价效应更为明显。统计范 围内的39家上海医药生物企业，CFO薪酬总额达4442.62万元，其平均年薪跃升至约113.91万元（中位数 102.20万元）。 这一数字相比全市场CFO平均薪酬高出39.8%（约32.43万元），凸显了上海作为高运营成本、高人才竞 争核心区域，叠加医药生物这一高附加值行业的强力薪酬溢价。 在上海地区医药生物行业上市公司CFO薪酬榜单中，奥浦迈（股票代码：688293.SH）的首席财务官倪 亮萍女士以140.29万元的年薪位列第九位。其2023年年薪为141.60万元，2024年略有下降，变化额 为-1.31万元，变化率为-0.93%。 倪亮萍女士在财务管理领域拥有丰富经验。公开资料显示，倪亮萍出生于1984年，毕业于上海财经大 学，目前为中欧国际商学院EMBA在读。她持有英国皇家特许管理会计师证书（CIMA）和全球特许管 理会计师证书（CGMA）。 在加入奥浦迈之前，倪亮萍女士的职业履历主要包括：2008年至2018年间历 ...

Core Viewpoint - Junshi Biosciences is positioned as a leading innovative pharmaceutical company in China, focusing on the development and commercialization of first-in-class and best-in-class drugs, with a comprehensive industry chain from drug discovery to large-scale production and global clinical research [2][3]. Company Overview - Junshi Biosciences was established on December 27, 2012, and went public on July 15, 2020. The company is headquartered in Shanghai and specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [7]. - The main revenue sources for the company include drug sales (84.18%), technology licensing and royalties (12.08%), and other income (3.73%) [7]. Recent Developments - On October 27, 2023, Junshi Biosciences announced a collaboration with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Advanced Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [3]. - The company’s subsidiary, JunTuo Biotech, is involved in the development of vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [3]. Financial Performance - For the period from January to March 2025, Junshi Biosciences reported a revenue of 5.01 billion yuan, representing a year-on-year growth of 31.46%. However, the net profit attributable to the parent company was -2.35 billion yuan, showing a year-on-year increase of 17.01% [8]. Market Activity - On August 6, 2023, Junshi Biosciences' stock rose by 4.61%, with a trading volume of 1.663 billion yuan and a turnover rate of 5.09%, bringing the total market capitalization to 42.382 billion yuan [1].

2024年，万泰生物实现营业收入22.45亿元，同比下降59.25%；归属于上市公司股东的净利润1.06亿 元，同比下降91.49%；归属于上市公司股东的扣除非经常性损益的净利润-1.86亿元，上年同期10.78亿 元；经营活动产生的现金流量净额为3.55亿元，同比下降76.91%。 中国经济网北京8月6日讯万泰生物（603392）(603392.SH)近日发布的2025年半年度业绩预亏公告显 示，经财务部门初步测算，预计2025年半年度实现归属于母公司所有者的净利润为-16,000万元 到-13,000万元，与上年同期相比，将出现亏损。预计2025年半年度实现归属于母公司所有者的扣除非 经常性损益的净利润为-26,000万元到-23,000万元。 上年同期，万泰生物实现归属于母公司所有者的净利润26,048万元，归属于母公司所有者的扣除非经常 性损益的净利润6,352万元。 万泰生物首次募集资金总额为3.82亿元，募集资金净额为3.18亿元。万泰生物2020年4月14日发布招股书 显示，募集资金中1.50亿元用于化学发光试剂制造系统自动化技术改造及国际化认证项目，1.50亿元用 于宫颈癌疫苗质量体系提升及国 ...

Group 1: New Stock Issuance and Performance - In July 2025, the North Exchange issued 2 new stocks, raising a total of 492 million yuan, with a cumulative issuance of 7 stocks and a total fundraising of 2.485 billion yuan from January to July 2025[5] - The first-day price increase for Dingjia Precision was 459.51%, with a theoretical subscription yield of +0.138%[3] - The cumulative yield for new stock subscriptions in 2024 was +3.99%, while for January to July 2025, it was +0.86%[3] Group 2: Subscription Trends and Market Dynamics - The median first-day price-to-earnings ratio (PEttm) for new stocks in July 2025 was 12x, up 90% from the previous month[5] - The median amount of frozen funds for new stock subscriptions was 621.68 billion yuan, an increase of 12.51% month-on-month, with a median online winning rate of 0.04%[5] - The number of effective subscription accounts for Dingjia Precision reached 659,600, a 14.24% increase from the previous issuance[5] Group 3: Future Projections and Risks - The forecast for new stock issuance in 2025 is set at 30 stocks, assuming a steady pace of one issuance per week[5] - The expected first-day price increase for new stocks is projected at 300%, with a neutral expectation for the online winning rate at 0.038%[5] - Risks include slower-than-expected issuance speed, lower-than-expected price increases, and potential macroeconomic downturns[5]

Market Overview - The three major indices in the A-share market opened slightly lower but fluctuated to turn positive during the morning session, with the Shanghai Composite Index at 3627.54 points, up 0.27%, the Shenzhen Component Index at 11158.42 points, up 0.46%, and the ChiNext Index at 2352.58 points, up 0.39% [1] Sector Performance - The leading sectors in terms of gains included military equipment (up 3.86%), military electronics (up 2.21%), and rubber products (up 1.96%) [2] - Conversely, the sectors with the largest declines were traditional Chinese medicine (down 1.91%), pharmaceutical commerce (down 1.12%), and chemical pharmaceuticals (down 1.04%) [2]

证券之星消息，8月5日，热景生物（688068）融资买入4279.76万元，融资偿还3906.82万元，融资净买 入372.94万元，融资余额2.99亿元，近3个交易日已连续净买入累计5630.15万元，近20个交易日中有13 个交易日出现融资净买入。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-08-05 | 372.94万 | 2.99亿 | 1.43% | | 2025-08-04 | 3413.39万 | 2.95 Z | 1.43% | | 2025-08-01 | 1843.83万 | 2.61亿 | 1.30% | | 2025-07-31 | -640.08万 | 2.43亿 | 1.34% | | 2025-07-30 | 130.27万 | 2.49亿 | 1.41% | | 交易日 | 两融余额(元) | 余额变动 (元) | 变动幅度 | | --- | --- | --- | --- | | 2025-08-05 | 2.99亿 | 372.94万 | 1.26% | | 2025-08 ...